coronary heart disease
Conditions
Interventions
continuation group of the maintenance dose by the clopidogrel(75mg/day)
It is change group from clopidogrel of the maintenance dose in prasugrel(3.75mg./day) of the maintenance dose
Sponsors
Graduate School of Medicine, University of Ryukyus Department of Cardiovascular Medicine, Nephrology and Neurology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The chronic coronary disease patient who is taking clopidogrel for more than one month.
Exclusion criteria
Exclusion criteria: 1)Dialysis 2)Dangerously ill liver disease patient 3)Malignant tumor of the activity 4)The patient that art of planned coronary revasculalization is not completed 5)PCI enforcement patients within 7 days 6)Dangerously ill heart failure patient(LVEFless than 30%. NYHA IV) 7)More than less than 50,000 number of the platelets /micro l or 500,000 /micro l, it is less than 30% of hematocrit or more than 50% 8)Bleeding patient 9)Patients who need treatment with anticoagulant 10)The patient who is participating in other clinical trials 11)Pregnant patient 12)the patient who judged that the medical attendant was inappropriate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Platelet aggregation ability (PRU in VerifyNow) at the time of clopidogrel remedy and the prasugrel remedy | — |
Secondary
| Measure | Time frame |
|---|---|
| Complications including a cardiovascular event and the bleeding until one year later. | — |
Countries
Japan
Contacts
Public ContactMasashi Iwabuchi
Graduate School of Medicine, University of Ryukyus Department of Cardiovascular Medicine, Nephrology and Neurology
Outcome results
None listed